Clinical trials: Limping
Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1
Pedicle Osteotomy for Stenosis Trial
This is a pivotal Randomized Clinical trial to compare the safety and effectiveness of the Pedicle Lengthening Osteotomy Procedure with implantation of the Altum® Device to open surgical decompression and Transforaminal Lumbar…
- Conditions
- Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1, Neurogenic Claudication
- Trial name
- POST (NCT03381677)
- Testing
- Pedicle Lengthening Osteotomy with Altum® Device, Control
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Innovative Surgical Designs
Symptomatic Lumbar Spinal Stenosis
Home-based Cycling for People With Lumbar Spinal Stenosis
The main objective of the study is to compare the efficacy on back-specific activity limitations at 4 months after-randomisation of home-based cycling using connected ergometric bicycles associated with usual care to usual care.
- Trial name
- FLEXCAL (NCT04075539)
- Testing
- Home-based cycling program, usual care
- Where
- France
- Volunteers
- 302 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peripheral Arterial Disease, Claudication
Effects of Passive Muscle Stretching on Vascular Function and Symptoms of PAD
Patients with peripheral arterial disease often have walking impairment due to insufficient oxygen supply to lower extremity skeletal muscle.
- Trial name
- NCT03288181
- Testing
- Muscle Stretch
- Volunteers
- 13 people
- Sponsor
- Tallahassee Research Institute, Inc.
Peripheral Artery Disease, Intermittent Claudication
Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients
This trial is evaluating if rivaroxaban 2.5 mg BID and aspirin 100 mg OD compared to aspirin alone improves on intermittent claudication distance in PAD patients.
- Trial name
- NCT04853719
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- 2 sites in Brazil
- Volunteers
- 88 people
- Sponsor
- Science Valley Research Institute
Intermittent Claudication, Cardiovascular Diseases
Acute Responses to Arm-Crank Exercise on Cardiovascular Function of Patients With Peripheral Artery Disease
The aim of this study is to analyze acute responses of arm-cranking exercise on cardiovascular function of peripheral arterial disease patients and compare it to the main exercise recommendation, walking exercise.
- Conditions
- Intermittent Claudication, Cardiovascular Diseases, Blood Pressure, Endothelial Dysfunction
- Trial name
- NCT05611021
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 17 people
- Sponsor
- University of Nove de Julho
Peripheral Artery Disease, Exercise
Response to Exercise and Nitric Oxide in PAD
RESIST PAD is a randomized trial of 200 PAD patients to establish: 1) whether a 12-week exercise intervention significantly increases Δ nitrite at 12-week follow-up, compared to control; 2) whether exercise "responders" have…
- Conditions
- Peripheral Artery Disease, Exercise, Intermittent Claudication, Nitric Oxide
- Trial name
- RESIST (NCT06657976)
- Testing
- Supervised Treadmill Exercise, Attention Control, Nitrate-Rich Beetroot Juice + supervised exercise therapy
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Peripheral Arterial Disease
Saving Life and Limb: FES for the Elderly With PAD
This study will take the first step to improve public health for millions of Americans with Peripheral Arterial Disease who have extreme difficulty walking due to leg pain.
- Trial name
- NCT02384980
- Testing
- FES (Gait MyoElectric Stimulator)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- MultiCare Health System Research Institute
Peripheral Arterial Disease
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities.
- Trial name
- NCT02842424
- Testing
- Ramipril
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Nebraska
Peripheral Arterial Disease
Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
This is a Phase 4, randomized clinical trial to evaluate whether addition of Vorapaxar 2.08 mg daily vs. placebo daily on background antiplatelet therapy, prescribed for 6 months to patients with established peripheral artery…
- Trial name
- XLPADTRACE (NCT02660866)
- Testing
- Vorapaxar 2.08 mg/d + background APT + SMT.
- Where
- 12 sites in United States
- Volunteers
- 200 people
- Sponsor
- North Texas Veterans Healthcare System
Peripheral Arterial Disease, Stenosis
FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.
- Conditions
- Peripheral Arterial Disease, Stenosis, Intermittent Claudication
- Trial name
- NCT00424866
- Testing
- FGF-1
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Venturis Therapeutics, Inc.
Intermittent Claudication
The Effects of Claudication Severity on Functional Outcomes
Peripheral artery disease (PAD) affects over 236 million people globally. A classic symptom of PAD is intermittent claudication (IC) which is associated with reductions in physical function.
- Trial name
- NCT04370327
- Testing
- Pain Free Exercise (PF), Moderate Claudication Pain Exercise (MOD-P), Maximal Claudication Pain Exercise (MAX-P)
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- University of Central Lancashire
Intermittent Claudication, PAD
Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC
This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of patients with PAD who presented with intermittent claudication.
- Conditions
- Intermittent Claudication, PAD, Atherosclerotic Ischemic Disease
- Trial name
- NCT03683628
- Testing
- PB-MNC therapy, No PB-MNC therapy
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Mahidol University
Peripheral Artery Disease, Intermittent Claudication
Observational Feasibility Study of Home-based Training With Therabands in PAD-patients
The study is an observational feasibility study to evaluate the feasibility of a combined aerobic+resistance training program in patients with IC.
- Trial name
- NCT04043546
- Testing
- aerobic+resistance exercise training program
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Peripheral Vascular Disease, Intermittent Claudication
Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions
The BRAVISSIMO trial wants to investigate in a controlled setting, the long-term (up to 24 months) outcome of the self-expanding nitinol Absolute Pro (Abbott Vascular) and the balloon-expandable Omnilink Elite (Abbott Vascular)…
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Critical Limb Ischemia
- Trial name
- BRAVISSIMO (NCT00764777)
- Testing
- iliac stenting
- Where
- 5 sites in Belgium
- Volunteers
- 325 people
- Sponsor
- Flanders Medical Research Program
Peripheral Artery Disease
Ankle-foot Orthoses for Peripheral Artery Disease
The primary aim of this study is to investigate the effect of an ankle foot orthoses (AFO) on the primary outcome of peak walking time (PWT) in patients with peripheral artery disease (PAD).
- Trial name
- NCT02280200
- Testing
- AFO to improve outcomes
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Minnesota
Peripheral Arterial Disease, Claudication
Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE)
The purpose of the study is to evaluate the intermediate and long-term effectiveness of stand-alone atherectomy treatment of peripheral arterial disease in the legs.
- Conditions
- Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
- Trial name
- NCT00883246
- Testing
- SilverHawk & TurboHawk Peripheral Plaque Excision System
- Volunteers
- 800 people
- Sponsor
- Medtronic Endovascular
Intermittent Claudication
Person-centered Follow up and Health Promotion Program After Revascularization for Intermittent Claudication
The overall aim of the study is to evaluate a nurse-led intervention (person-centered follow up and health promotion) program in comparison to standard follow up for patients treated with surgical or endovascular…
- Trial name
- FASTIC (NCT03283358)
- Testing
- Person-centered follow up
- Where
- 2 sites in Sweden
- Volunteers
- 213 people
- Sponsor
- Karolinska Institutet
Superficial Femoral Artery Stenosis, Superficial Femoral Artery Occlusion
Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)
This is a prospective randomized controlled trial to compare clinical improvement, cost effectiveness and patency rates between new and improved Nitinol stents and open bypass surgery in the superficial femoral artery disease.
- Conditions
- Superficial Femoral Artery Stenosis, Superficial Femoral Artery Occlusion, Claudication, Rest Pain
- Trial name
- ROBUST (NCT01602159)
- Testing
- Open Bypass Surgery, Angioplasty and Stenting
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Cardiovascular Disease
Evaluation of Patients With Heart Disease Not Eligible for Research Protocols
An important mission of the National Institutes of Health (NIH) is to develop and carry out research studies designed to improve understanding of disease processes and treatments.
- Trial name
- NCT00001458
- Where
- United States
- Volunteers
- 7,829 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Peripheral Arterial Occlusive Disease
Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication
The primary objective is to assess safety and efficacy of two different doses of NV1FGF as compared to placebo. The secondary objective is to assess the pharmacokinetics of NV1FGF and FGF-1 protein.
- Trial name
- TALISMAN 211 (NCT01157871)
- Testing
- XRP0038 (NV1FGF)
- Where
- 4 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Sanofi